A company timeline

It’s been a long road from start-up to verge of FDA approval

April 24, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

1989 Vertex founded by Joshua Boger

1991 Vertex launches initial public offering of 3 million shares

1993 Vertex begins research on hepatitis C and AIDS drugs

1994 Publication of “The Billion-Dollar Molecule,’’ a book about Vertex

1998 Vertex begins work on cystic fibrosis drugs

1999 Agenerase, a drug jointly developed by Vertex and GlaxoSmithKline for treatment of HIV, approved by the FDA

2001 Hepatitis C drug, telaprevir, selected for clinical trials

2005 Based on early positive results, FDA grants fast-track designation for telaprevir to accelerate the review process

2006 Vertex forms collaboration with Johnson & Johnson to develop and commercialize telaprevir

2008 Joshua Boger announces retirement; Matthew Emmens succeeds him as chief executive and chairman

2010 Vertex announces final test results of telaprevir, completes new drug application

2011 FDA grants priority review to telaprevir; decision on approval expected Thursday